Among them, PCDH17 has been reported as a negative regulator of the Wnt/β-catenin pathway [30], and since our group has already established the prognostic significance of several Wnt antagonists in AML [31–33], subsequent studies focused on the clinical impact of PCDH17 gene. The gene discussed is PCDH17; the disease is acute myeloid leukemia.